

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT07262983

| | |
|------------|---|
| Status | RECRUITING |
| Phase | Phase 1 |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 20 participants |

Key Eligibility Criteria

Inclusion (16)

- To be eligible to participate in this study, an individual must meet all of the following criteria:
 - Must be able to understand and provide informed consent or assent.
 - Aged ≥ 12 years.
 - Documented STAT3 variant causing hyper-IgE syndrome.
 - Enrollment in NIH protocol 00-I-0159, Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES).
- ... and 11 more (see full listing online)

Exclusion (52)

- An individual who meets any of the following criteria will be excluded from participation in this study:
 - Known history of hypersensitivity to baricitinib or other JAK inhibitors.
 - Current or recent use of any investigational drug/intervention (within 6 months or 5 half-lives, whichever is longer, prior to Day 0) except for COVID-19 vaccines or therapies that have been granted an FDA emergency authorization.
 - Scheduled to participate in another clinical study involving an investigational drug during the course of this study.
 - Use of systemic immunosuppressive or immune-modulating agents within 90 days prior to Day 0, except systemic steroids ≤ 10 mg of prednisone equivalent per day.
- ... and 47 more (see full listing online)

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States